|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh CR and Kathiresan K: Molecular
understanding of lung cancers - a review. Asian Pac J Trop Biomed.
4:(Suppl 1). S35–S41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Novaes FT, Cataneo DC, Junior RL Ruiz,
Defaveri J, Michelin OC and Cataneo AJM: Lung cancer: histology,
staging, treatment and survival. J Bras Pneumol. 34:595–600.
2008.(In English and Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Youlden DR, Cramb SM and Baade PD: The
international epidemiology of lung cancer: geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson JL, Pillai S and Chellappan SP:
Genetic and biochemical alterations in non-small cell lung cancer.
Biochem Res Int. 2012:9404052014.
|
|
6
|
Rodenhuis S, Slebos RJ, Boot AJ, Evers SG,
Mooi WJ, Wagenaar SS, van Bodegom PC and Bos JL: Incidence and
possible clinical significance of K-ras oncogene activation in
adenocarcinoma of the human lung. Cancer Res. 48:5738–5741.
1988.PubMed/NCBI
|
|
7
|
Liu H, Radisky DC, Yang D, Xu R, Radisky
ES, Bissell MJ and Bishop JM: MYC suppresses cancer metastasis by
direct transcriptional silencing of αv and β3 integrin subunits.
Nat Cell Biol. 14:567–574. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prins J, De Vries EG and Mulder NH: The
myc family of oncogenes and their presence and importance in
small-cell lung carcinoma and other tumour types. Anticancer Res.
13:1373–1385. 1993.PubMed/NCBI
|
|
9
|
Kurup A and Hanna NH: Treatment of small
cell lung cancer. Crit Rev Oncol Hematol. 52:117–126. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumarakulasinghe NB, van Zanwijk N and Soo
RA: Molecular targeted therapy in the treatment of advanced stage
non-small cell lung cancer (NSCLC). Respirology. 20:370–378. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chew CS, Chen X, Parente JA, Tarrer S,
Okamoto C and Qin HY: Lasp-1 binds to non-muscle F-actin in vitro
and is localized within multiple sites of dynamic actin assembly in
vivo. J Cell Sci. 115:4787–4799. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakagawa H, Terasaki AG, Suzuki H, Ohashi
K and Miyamoto S: Short-term retention of actin filament binding
proteins on lamellipodial actin bundles. FEBS Lett. 580:3223–3228.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grunewald TG, Kammerer U, Schulze E,
Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1
influences zyxin localization, inhibits proliferation and reduces
migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang
S, Sun X, Li J, Deng Y, Jiang Y and Ding Y: Promotion of colorectal
cancer growth and metastasis by the LIM and SH3 domain protein 1.
Gut. 59:1226–1235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salvi A, Bongarzone I, Miccichè F, Arici
B, Barlati S and De Petro G: Proteomic identification of LASP-1
down-regulation after RNAi urokinase silencing in human
hepatocellular carcinoma cells. Neoplasia. 11:207–219. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang H, Li W, Jin X, Cui S and Zhao L: LIM
and SH3 protein 1, a promoter of cell proliferation and migration,
is a novel independent prognostic indicator in hepatocellular
carcinoma. Eur J Cancer. 49:974–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiyomaru T, Enokida H, Kawakami K,
Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa
M: Functional role of LASP1 in cell viability and its regulation by
microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Butt E, Gambaryan S, Göttfert N, Galler A,
Marcus K and Meyer HE: Actin binding of human LIM and SH3 protein
is regulated by cGMP-and cAMP-dependent protein kinase
phosphorylation on serine 146. J Biol Chem. 278:15601–15607. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li B, Zhuang L and Trueb B: Zyxin
interacts with the SH3 domains of the cytoskeletal proteins
LIM-nebulette and Lasp-1. J Biol Chem. 279:20401–20410. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schreiber V, Moog-Lutz C, Régnier CH,
Chenard MP, Boeuf H, Vonesch JL, Tomasetto C and Rio MC: Lasp-1, a
novel type of actin-binding protein accumulating in cell membrane
extensions. Mol Med. 4:675–687. 1998.PubMed/NCBI
|
|
22
|
Chew CS, Parente JA Jr, Zhou CJ, Baranco E
and Chen X: Lasp-1 is a regulated phosphoprotein within the cAMP
signaling pathway in the gastric parietal cell. Am J Physiol.
275:C56–C67. 1998.PubMed/NCBI
|
|
23
|
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P,
Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al: A global map of
p53 transcription-factor binding sites in the human genome. Cell.
124:207–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pfeifer GP, Denissenko MF, Olivier M,
Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogens,
DNA damage and p53 mutations in smoking-associated cancers.
Oncogene. 21:7435–7451. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang B, Feng P, Xiao Z and Ren EC: LIM and
SH3 protein 1 (Lasp1) is a novel p53 transcriptional target
involved in hepatocellular carcinoma. J Hepatol. 50:528–537. 2009.
View Article : Google Scholar : PubMed/NCBI
|
